Halozyme Therapeutics, Inc.
HALO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $8,596,841 | $6,312,263 | $7,862,349 | $6,043,471 |
| - Cash | $419,665 | $61,861 | $176,328 | $115,850 |
| + Debt | $1,510,757 | $1,509,100 | $1,507,447 | $1,505,798 |
| Enterprise Value | $9,687,933 | $7,759,502 | $9,193,468 | $7,433,419 |
| Revenue | $354,264 | $325,719 | $264,861 | $298,008 |
| % Growth | 8.8% | 23% | -11.1% | – |
| Gross Profit | $299,022 | $279,360 | $216,458 | $255,953 |
| % Margin | 84.4% | 85.8% | 81.7% | 85.9% |
| EBITDA | $284,625 | $229,834 | $168,802 | $203,169 |
| % Margin | 80.3% | 70.6% | 63.7% | 68.2% |
| Net Income | $175,225 | $165,160 | $118,095 | $137,012 |
| % Margin | 49.5% | 50.7% | 44.6% | 46% |
| EPS Diluted | 1.43 | 1.33 | 0.93 | 1.06 |
| % Growth | 7.5% | 43% | -12.3% | – |
| Operating Cash Flow | $178,597 | $99,711 | $154,221 | $178,467 |
| Capital Expenditures | -$3,030 | -$1,563 | -$950 | -$3,052 |
| Free Cash Flow | $175,567 | $98,148 | $153,271 | $175,415 |